Items where authors include "James, N.D."

Article

Gordon, N.S., McGuigan, E.K., Ondasova, M. et al. (12 more authors) (2024) Comparison and combination of mutation and methylation-based urine tests for bladder cancer detection. Biomarker Research, 12. 133. ISSN 2050-7771

Parker, C.C. orcid.org/0000-0001-6512-124X, Petersen, P.M., Cook, A.D. orcid.org/0000-0003-4417-2632 et al. (55 more authors) (2024) Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047). Annals of Oncology, 35 (7). pp. 656-666. ISSN 0923-7534

Sydes, M.R., Murray, M.L., Ahmed, S. et al. (25 more authors) (2024) Getting our ducks in a row: The need for data utility comparisons of healthcare systems data for clinical trials. Contemporary Clinical Trials, 141. 107514. ISSN 1551-7144

Smith, T.A.D., West, C.M.L. orcid.org/0000-0002-0839-3449, Joseph, N. et al. (15 more authors) (2024) A hypoxia biomarker does not predict benefit from giving chemotherapy with radiotherapy in the BC2001 randomised controlled trial. eBioMedicine, 101. 105032. ISSN 2352-3964

Nanton, V. orcid.org/0000-0002-9553-822X, Bryan, R.T. orcid.org/0000-0003-2853-4293, Pope, A.M. et al. (11 more authors) (2023) Boosting and broadening recruitment to UK cancer trials: towards a blueprint for action. BMJ Oncology, 2 (1). e000092. ISSN 2752-7948

Bryan, R.T., Pirrie, S.J., Abbotts, B. et al. (26 more authors) (2023) Selenium and vitamin E for prevention of non–muscle-invasive bladder cancer recurrence and progression. JAMA Network Open, 6 (10). e2337494. ISSN 2574-3805

Mintz, H.P. orcid.org/0000-0003-1583-6268, Dosanjh, A.R.S. orcid.org/0000-0002-4522-7722, Parsons, H. orcid.org/0000-0002-2765-3728 et al. (4 more authors) (2023) Making administrative healthcare systems clinical data the future of clinical trials: lessons from BladderPath. BMJ Oncology, 2 (1). e000038. ISSN 2752-7948

James, N.D., Liu, W., Pirrie, S. orcid.org/0000-0002-2894-2230 et al. (9 more authors) (2022) TUXEDO: a phase I/II trial of cetuximab with chemoradiotherapy in muscle-invasive bladder cancer. BJU International, 131 (1). pp. 63-72. ISSN 1464-4096

James, N.D., Ali, A., Pope, A. et al. (5 more authors) (2022) Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer. BJUI Compass, 3 (6). pp. 484-493. ISSN 2688-4526

Parker, C.C., James, N.D. orcid.org/0000-0002-7314-8204, Brawley, C.D. orcid.org/0000-0003-3641-278X et al. (43 more authors) (2022) Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial. PLOS Medicine, 19 (6). e1003998. ISSN 1549-1277

Hussain, S.A. orcid.org/0000-0003-1552-511X, Lester, J.F., Jackson, R. et al. (17 more authors) (2022) Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE) : a double-blind, randomised, phase 2 trial. The Lancet Oncology, 23 (5). pp. 650-658. ISSN 1470-2045

Galesloot, T.E., Grotenhuis, A.J., Kolev, D. et al. (16 more authors) (2022) Genome-wide meta-analysis identifies novel genes associated with recurrence and progression in non–muscle-invasive bladder cancer. European Urology Oncology, 5 (1). pp. 70-83. ISSN 2588-9311

Clarke, N.W., Ali, A., Ingleby, F.C. et al. (47 more authors) (2019) Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Annals of Oncology, 30 (12). pp. 1992-2003. ISSN 0923-7534

Hussain, S.A. orcid.org/0000-0003-1552-511X, Palmer, D.H., Syn, W.K. et al. (11 more authors) (2017) Gene expression profiling in bladder cancer identifies potential therapeutic targets. International Journal of Oncology, 50 (4). pp. 1147-1159. ISSN 1019-6439

Andronis, L., Goranitis, I., Pirrie, S. et al. (19 more authors) (2016) Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747). BJU International. ISSN 1464-4096

James, N.D., Pirrie, S.J., Pope, A.M. et al. (19 more authors) (2016) Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both. JAMA Oncology, 2 (4). p. 493. ISSN 2374-2437

Ward, D.G., Baxter, L., Gordon, N.S. et al. (15 more authors) (2016) Multiplex PCR and Next Generation Sequencing for the Non-Invasive Detection of Bladder Cancer. PLOS ONE, 11 (2). e0149756-e0149756. ISSN 1932-6203

Bryan, R.T., Evans, T., Dunn, J.A. et al. (6 more authors) (2015) A Comparative Analysis of the Influence of Gender, Pathway Delays, and Risk Factor Exposures on the Long-term Outcomes of Bladder Cancer. European Urology Focus, 1 (1). 82 - 89.

Bryan, R.T., Shimwell, N.J., Wei, W. orcid.org/0000-0003-1288-6999 et al. (7 more authors) (2014) Urinary EpCAM in urothelial bladder cancer patients: characterisation and evaluation of biomarker potential. British Journal of Cancer, 110 (3). pp. 679-685. ISSN 0007-0920

Shimwell, N.J., Bryan, R.T., Wei, W. orcid.org/0000-0003-1288-6999 et al. (6 more authors) (2013) Combined proteome and transcriptome analyses for the discovery of urinary biomarkers for urothelial carcinoma. BRITISH JOURNAL OF CANCER, 108 (9). pp. 1854-1861. ISSN 0007-0920

Proceedings Paper

Brown, J.E. orcid.org/0000-0003-4960-3032, Handforth, C., Walsh, J. orcid.org/0000-0002-7122-2650 et al. (5 more authors) (2019) 857P - Baseline fracture risk in men with prostate cancer starting the STAMPEDE trial. In: Annals of Oncology. 44th ESMO Congress (ESMO 2019), 27 Sep - 01 Oct 2019, Barcelona, Spain. Elsevier BV , v334-v335.